JP2002520294A - インターロイキン−１５拮抗薬によるセリアック病の治療 - Google Patents

インターロイキン−１５拮抗薬によるセリアック病の治療

Info

Publication number
JP2002520294A
JP2002520294A JP2000558841A JP2000558841A JP2002520294A JP 2002520294 A JP2002520294 A JP 2002520294A JP 2000558841 A JP2000558841 A JP 2000558841A JP 2000558841 A JP2000558841 A JP 2000558841A JP 2002520294 A JP2002520294 A JP 2002520294A
Authority
JP
Japan
Prior art keywords
cells
antagonist
expression
fas
gliadin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000558841A
Other languages
English (en)
Japanese (ja)
Inventor
ロンデイ，マルコ
クアランティーノ，ソニア
マイウーリ，ルイージ
Original Assignee
ザ マティルダ アンド テレンス ケネディ インスティチュート オブ リューマトロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ マティルダ アンド テレンス ケネディ インスティチュート オブ リューマトロジー filed Critical ザ マティルダ アンド テレンス ケネディ インスティチュート オブ リューマトロジー
Publication of JP2002520294A publication Critical patent/JP2002520294A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
JP2000558841A 1998-07-10 1999-07-09 インターロイキン−１５拮抗薬によるセリアック病の治療 Pending JP2002520294A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9814892.7 1998-07-10
GBGB9814892.7A GB9814892D0 (en) 1998-07-10 1998-07-10 Treatment of celiac disease
PCT/GB1999/002201 WO2000002582A2 (fr) 1998-07-10 1999-07-09 Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15

Publications (1)

Publication Number Publication Date
JP2002520294A true JP2002520294A (ja) 2002-07-09

Family

ID=10835232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558841A Pending JP2002520294A (ja) 1998-07-10 1999-07-09 インターロイキン−１５拮抗薬によるセリアック病の治療

Country Status (5)

Country Link
EP (1) EP1096949A2 (fr)
JP (1) JP2002520294A (fr)
CA (1) CA2333923A1 (fr)
GB (1) GB9814892D0 (fr)
WO (1) WO2000002582A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528348A (ja) * 2003-02-26 2007-10-11 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002332628B2 (en) 2001-08-23 2007-07-26 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
CU23093A1 (es) 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
DE602005026287D1 (de) 2004-04-16 2011-03-24 Univ Alberta Anti-gluten-eigelb-antikörper zur behanldung von zoeliakie
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
CA2768965C (fr) 2009-08-14 2019-06-04 George N. Pavlakis Utilisation d'il-15 pour ameliorer la production thymique et pour traiter la lymphopenie
US20180002417A1 (en) * 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
WO2018041989A1 (fr) * 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement de la maladie coeliaque réfractaire de type 2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
WO1997041232A1 (fr) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonistes de l'interleukine-15

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528348A (ja) * 2003-02-26 2007-10-11 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
JP4892335B2 (ja) * 2003-02-26 2012-03-07 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Also Published As

Publication number Publication date
WO2000002582A3 (fr) 2000-03-16
GB9814892D0 (en) 1998-09-09
EP1096949A2 (fr) 2001-05-09
WO2000002582A2 (fr) 2000-01-20
CA2333923A1 (fr) 2000-01-20

Similar Documents

Publication Publication Date Title
D'Elios et al. In vivo CD30 expression in human diseases with predominant activation of Th2‐like T cells
US7763434B2 (en) Antagonists of interleukin-15
Mita et al. Receptors for T cell-replacing factor/interleukin 5. Specificity, quantitation, and its implication.
EA027623B1 (ru) Антитела, направленные против icos, и их применения
US20100086517A1 (en) Enhancement of B cell proliferation by IL-15
JP2019506843A (ja) 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン−１０及びその使用方法
JPH11500908A (ja) インターロイキン−１５のアンタゴニスト
JP2002520294A (ja) インターロイキン−１５拮抗薬によるセリアック病の治療
AU2006342792A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
US20200123225A1 (en) Methods and compositions for modulating the activity of the interleukin-35 receptor complex
US20130230524A1 (en) Protein Involved in Ovarian Cancer
JP4299887B2 (ja) 免疫学的疾患の治療のための治療剤としての、可溶性リンホトキシン―βレセプター、抗リンホトキシンレセプター抗体、および抗リンホトキシンリガンド抗体
JP2022058412A (ja) 修飾自己エピトープに対する抗腫瘍免疫応答
WO2019129892A1 (fr) Récepteurs de lymphocytes t pour variants d'épissage de protéasome spécifiques d'une tumeur et leurs utilisations
EP1222212A1 (fr) Mutants il13
US20060147478A1 (en) Protein involved in carcinoma
EP2182005A1 (fr) Gène encodant un homologue P-glycoprotéine humain multi-résistant aux médicaments pour le chromosome 7p15-21 et utilisations associées
AU2013200914B2 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
JP2016069314A (ja) 免疫抑制剤
EP2527371B1 (fr) Procédé pour le traitement de glomérulonéphrite
WO2005023300A2 (fr) Proteine intervenant dans le carcinome
WO2006000753A2 (fr) Proteine impliquee dans le cancer du colon, colorectal, des ovaires, des poumons et/ou du foie
MX2007004094A (en) Enhancement of b cell proliferation by il-15
WO2005019257A1 (fr) Proteine impliquee dans le cancer du pancreas
MXPA99003801A (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases